International expert opinion on patient-tailored management of soft tissue sarcomas

European Journal of Cancer

Volumn 50, Issue 4, 2014, Pages 679-689

  Blay, Jean Yves ^a   Sleijfer, Stefan ^b   Schöffski, Patrick ^c   Kawai, Akira ^d   Brodowicz, Thomas ^e   Demetri, George D ^f   Maki, Robert G ^g  

^a UNIVERSITÉ LYON 1   (France)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Management; Soft tissue sarcoma; Treatment

Indexed keywords

MANAGEMENT; SOFT TISSUE SARCOMA; TREATMENT;

ALGORITHMS; CONSENSUS; DECISION MAKING; EXPERT TESTIMONY; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL COOPERATION; MODELS, BIOLOGICAL; PATIENT-CENTERED CARE; SARCOMA;

EID: 84894061172     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.11.011     Document Type: Review

References (52)

1. C.D.M. Fletcher, K. Unni, and F. Mertens World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone 2002 IARC Press Lyon
2. R.F. Riedel Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches Cancer 118 2012 1474 1485
3. ESMO/European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 2012 vii92 vii99
4. P. Rutkowski, M. Van Glabbeke, and C.J. Rankin et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials J Clin Oncol 28 2010 1772 1779
5. G.D. Demetri, M. von Mehren, and C.R. Antonescu et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors J Natl Comp Canc Netw 8 Suppl. 2 2010 S1 S41 quiz S42-4
6. N. Penel, B.N. Bui, and J.O. Bay et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study J Clin Oncol 26 2008 5269 5274
7. M. Schlemmer, P. Reichardt, and J. Verweij et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group Eur J Cancer 44 2008 2433 2436
8. R. Garcia-Carbonero, J.G. Supko, and R.G. Maki et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clinc Oncol 23 2005 5484 5492
9. A. Gronchi, B.N. Bui, and S. Bonvalot et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma Ann Oncol 23 2012 771 776
10. D. Pink, T. Lindner, A. Mrozek, A. Kretzschmar, P.C. Thuss-Patience, and B. Dorken et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature Gynecol Oncol 101 2006 464 469
11. P.G. Casali Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas Ann Oncol 23 Suppl 10 2012 x167 x169
12. S. George, J.Y. Blay, P.G. Casali, A. Le Cesne, P. Stephenson, and S.E. Deprimo et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Eur J Cancer 45 2009 1959 1968
13. S. Stacchiotti, E. Tamborini, and A. Marrari et al. Response to sunitinib malate in advanced alveolar soft part sarcoma Clin Cancer Res 15 2009 1096 1104
14. N. Penel, M.V. Glabbeke, and S. Mathoulin-Pelissier et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study Br J Cancer 104 2011 1544 1550
15. A. Italiano, S. Mathoulin-Pelissier, and A.L. Cesne et al. Trends in survival for patients with metastatic soft-tissue sarcoma Cancer 117 2011 1049 1054
16. S. Sleijfer, M. Ouali, and M. van Glabbeke et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer 46 2010 72 83
17. M. Van Glabbeke, A.T. van Oosterom, and J.W. Oosterhuis et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol 17 1999 150 157
18. B. Kasper, M. Ouali, and M. van Glabbeke et al. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931 Eur J Cancer 49 2013 449 456
19. M. Eriksson Histology-driven chemotherapy of soft-tissue sarcoma Ann Oncol 21 Suppl 7 2010 vii270 vii276
20. F. Ducimetière, A. Lurkin, and D. Ranchère-Vince et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing PLoS One 6 2011 e20294
21. A. Ferrari, P. Dileo, and M. Casanova et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution Cancer 98 2003 571 580
22. G.D. Demetri, P. Reichardt, and Y.K. Kang et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 295 302
23. R. Garcia-Carbonero, J.G. Supko, and J. Manola et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 2004 1480 1490
24. S.H. Lee, M.H. Chang, and K.K. Baek et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients Oncology 80 2011 257 261
25. J.H. Edmonson, L.M. Ryan, and R.H. Blum et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol 11 1993 1269 1275
26. J.H. Edmonson, L.M. Ryan, C.I. Falkson, D.G. Hicks, and R.H. Blum Phase II study of ifosfamide+doxorubicin in patients with advanced synovial sarcomas (e1793): a trial of the Eastern Cooperative Oncology group Sarcoma 7 2003 9 11
27. P.A. Cassier, H. Gelderblom, and S. Stacchiotti et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis Cancer 118 2012 1649 1655
28. S. Kummar, D. Allen, and A. Monks et al. Cediranib for metastatic alveolar soft part sarcoma J Clin Oncol 31 2013 2296 2302
29. D. Tural, N. Molinas Mandel, and S. Dervisoglu Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome Jpn J Clin Oncol 42 2012 420 426
30. J.E. Butrynski, D.R. D'Adamo, and J.L. Hornick et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor N Engl J Med 363 2010 1727 1733
31. R. Grimer, I. Judson, D. Peake, and B. Seddon Guidelines for the management of soft tissue sarcomas Sarcoma 2010 2010 506182
32. Dacarbazine Summary of Product Characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/1088/SPC/ Dacarbazine+100mg%2c+200mg%2c+500mg%2c+1000mg/. Accessed January 2013.
33. M.S. Park, S.R. Patel, and J.A. Ludwig et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor Cancer 117 2011 4939 4947
34. P.G. Casali, S. Stacchiotti, and E. Palassini et al. Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT) J Clin Oncol 27 2009 10571
35. A. Italiano, M. Toulmonde, A. Cioffi, N. Penel, N. Isambert, and E. Bompas et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival Ann Oncol 23 2012 1601 1607
36. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
37. V. Karavasilis, B.M. Seddon, S. Ashley, O. Al-Muderis, C. Fisher, and I. Judson Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer 112 2008 1585 1591
38. J. Fayette, E. Martin, and S. Piperno-Neumann et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases Ann Oncol 18 2007 2030 2036
39. T. Wiklund, G. Saeter, H. Strander, T. Alvegard, and C. Blomqvist The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience Eur J Cancer 33 1997 357 361
40. J.Y. Blay, M. van Glabbeke, and J. Verweij et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy Eur J Cancer 39 2003 64 69
41. G.D. Demetri, S. Antonia, and R.S. Benjamin et al. Soft tissue sarcoma J Natl Comp Cancer Network 8 2010 630 674
42. J.B. Putnam Jr., and J.A. Roth Surgical treatment for pulmonary metastases from sarcoma Hematol Oncol Clin North Am 9 1995 869 887
43. Votrient 200 mg and 400 mg film coated tablets. Summary of product characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/23148/ SPC/Votrient+200+mg+and+400+mg+film+coated+tablets/. Accessed December 2012.
44. Doxorubicin 2 mg/ml concentrate for solution for infusion. Summary of product characteristics. Available from: http://www.medicines.org.uk/EMC/ medicine/25946/SPC/Doxorubicin+2+mg+ml+Concentrate+for+Solution+for+Infusion/. Accessed December 2012.
45. Yondelis 0.25 mg powder for concentrate for solution for infusion/Yondelis 1 mg powder for solution for infusion. Available from: http://www.medicines.org.uk/EMC/medicine/20457/SPC/Yondelis+0. 25+mg+powder+for+concentrate+for+solution+for+infusion+Yondelis+1+mg+powder+for +concentrate+for+solution+for+infusion/. Acessed January 2013.
46. Ifosfamide injection 2 g. Summary of product characteristics. Available from: http://www.ecomm.baxter.com/ecatalog/loadResource.do?bid=53536. Accessed December 2012.
47. EMC. Gemcitabine 100 mg/ml concentrate for solution for infusion 2012. Available from: http://www.medicines.org.uk/EMC/medicine/27136/SPC/ Gemcitabine+100+mg+ml+Concentrate+for+Solution+for+Infusion/. Accessed December 2012.
48. EMC. Paclitaxel 6 mg/ml concentrate for solution for infusion 2012. Available from: http://www.medicines.org.uk/EMC/medicine/15842/SPC/ Paclitaxel+6+mg+ml+concentrate+for+solution+for+infusion/. Accessed December 2012.
49. EMC. Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion 2012. Available from: http://www.medicines.org.uk/EMC/medicine/26771/SPC/ Docetaxel+Accord+160+mg+8+ml+concentrate+for+solution+for+infusion/. Accessed December 2012.
50. Letrozole 2.5 mg film-coated tablets summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/24764/SPC/Letrozole+2. 5+mg+film-coated+tablets/. Accessed December 2012.
51. Anastrozole 1 mg film-coated tablets Available from: http://www. medicines.org.uk/emc/medicine/27391/SPC/Anastrozole+1+mg+film-coated+tablets/. Accessed December 2012.
52. J.C. Weeks, P.J. Catalano, and A. Cronin et al. Patients' expectations about effects of chemotherapy for advanced cancer N Engl J Med 367 2012 1616 1625